Cryptogenic organizing pneumonia primary prevention

	Cryptogenic Organizing Pneumonia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cryptogenic organizing pneumonia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic study of choice
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
Electrocardiogram
Ultrasonography/Echocardiography
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cryptogenic organizing pneumonia primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cryptogenic organizing pneumonia primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cryptogenic organizing pneumonia primary prevention
CDC on Cryptogenic organizing pneumonia primary prevention
Cryptogenic organizing pneumonia primary prevention in the news
Blogs on Cryptogenic organizing pneumonia primary prevention
Directions to Hospitals Treating Cryptogenic organizing pneumonitis
Risk calculators and risk factors for Cryptogenic organizing pneumonia primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]

Overview

Effective measures for the primary prevention of cryptogenic organizing pneumonia is elimination of the cause and appropriate treatment.

Effective measures for the primary prevention of cryptogenic organizing pneumonia include:
- Elimination of the cause is important preventive measure.
- Occupational and environmental cryptogenic organizing pneumonia are prevented by elimination of exposure to the agent.^[1]

↑ Burton CM, Iversen M, Carlsen J, Andersen CB (September 2008). "Interstitial inflammatory lesions of the pulmonary allograft: a retrospective analysis of 2697 transbronchial biopsies". Transplantation. 86 (6): 811–9. doi:10.1097/TP.0b013e3181852f02. PMID 18813106.